AGA‑Guided Management of Gastroparesis and Medication Safety in Young Adults with Neurodevelopmental Disorders

1. Medication Review and Elimination of Gastric‑Motility‑Impeding Drugs

Discontinue any agents known to delay gastric emptying—such as topiramate, opioid analgesics, and GLP‑1 receptor agonists—to improve gastroparesis symptoms (American Gastroenterological Association guideline, strong recommendation) 1.

Initiate a small‑particle, low‑fat, low‑residue diet before or alongside pharmacologic therapy to enhance gastric emptying (AGA guideline, strong recommendation) [1][2]4.

Start metoclopramide 5 mg three times daily before meals as the preferred first‑line prokinetic (AGA guideline, strong recommendation) [1][5]2.
Patients receiving concurrent psychotropic medications (e.g., SSRIs) have an increased risk of tardive dyskinesia and other movement disorders; however, the absolute risk remains low (moderate evidence) [5][6]2.
FDA black‑box warning for tardive dyskinesia applies to metoclopramide (strong evidence) [5][6]2.
Monitor for extrapyramidal or movement disorders at 4–8 weeks and continuously thereafter (moderate evidence) [5][2]7.
Consider drug holidays of 1–4 weeks after every 8–12 weeks of therapy to improve tolerability (moderate evidence) [5][6]8.

If metoclopramide is not tolerated, use low‑dose erythromycin (40–150 mg before meals) as an alternative prokinetic (AGA guideline, moderate recommendation) [1][5]8.
Prefer erythromycin ethylsuccinate oral suspension for better tolerability at lower doses (moderate evidence) [1][5]8.
Implement a “3 weeks on / 1 week off” schedule to prevent tachyphylaxis (moderate evidence) [5][8].
Monitor electrocardiogram for QT‑interval prolongation and be aware of CYP3A‑mediated drug interactions (moderate evidence) [5][8].

Use 5‑HT₃ antagonists (ondansetron), H₁ antagonists (promethazine), or D₂ antagonists (prochlorperazine) as needed to control nausea and vomiting without impairing gastric emptying (AGA guideline, strong recommendation) [1][5][6][2]3.

Assess efficacy and tolerability of gastroparesis medications (moderate evidence) [1][2][3][7].
Specifically monitor for movement disorders when metoclopramide is used (moderate evidence) [5][2]7.

Continue surveillance for extrapyramidal symptoms throughout metoclopramide therapy (moderate evidence) [5][2]7.
For patients on erythromycin, perform periodic ECGs to detect QT prolongation (moderate evidence) [5][8].
Re‑evaluate the need for drug holidays to maintain efficacy and minimize adverse effects (moderate evidence) [5][6]8.

Metoclopramide + Citalopram – Both agents can prolong the QT interval; obtain baseline and follow‑up ECGs when co‑administered (moderate evidence) [5][8].
Erythromycin + Citalopram – Erythromycin’s CYP3A inhibition may increase citalopram plasma concentrations; monitor for serotonin‑related toxicity (moderate evidence) [5][8].
Patients on any psychotropic medication have a heightened risk of metoclopramide‑related adverse effects, underscoring the need for vigilant monitoring (moderate evidence) [5][6][2][3]7.